Of the 159 respondents who needed prior authorization, 79 (49.7%) reported a long wait or no approval by the time of the survey [1]. That included 29 who received approval after more than seven days and 50 who were still waiting or had never been approved. Among people currently taking a weight-management medication, 32.4% reported a gap of two weeks or more.
Studies of why people stop GLP-1 treatment often report cost as a reason. This survey also asked what happened when insurance or prior authorization interrupted access to the medication.
Read the sampling frame first
Invitations went to adults identified from one academic medical center’s records. Each had at least one GLP-1 prescription in the preceding six years and a subsequent gap of more than 90 days. [1] The study used prescription records to identify the gap.
Of 4,890 invited people, 261 responded (5.3%). A prescription gap can include people who later restarted treatment. The single-center sample and low response rate limit how well the results represent other patients.
What respondents described
In all, 60.9% reported a prior-authorization requirement. Among the 159 who needed it, 38 reported approval in fewer than three days, and 42 reported approval in three to seven days. Those times describe survey responses from one medical center.
The things that worked were interpersonal: 76.2% knew whom to contact about their medication, and 70.7% reported timely responses from their care team. The things that failed were structural: cross-clinic coordination at 54.1% and visibility into what needed to happen next at 52.2%.
The authors also built an exploratory Continuity-of-Care Index for this survey, scored 0 to 100. It averaged 69.5 across 242 respondents and differed sharply by where people were seen. The median was 82.1 at a dedicated weight-management clinic against 60.7 in primary care, Kruskal-Wallis p < 0.001. That is their own instrument rather than a standard measure, and the direction is plain enough.
Where the delay sits in the wider funnel
A national cohort of 4,555 US adults measured the same journey from further back [2]. Awareness ran at 81.6% and use at 8.3%. Among people who attempted treatment, 49.9% never obtained the drug.
Participants who reported healthcare access barriers were more likely to report an unsuccessful attempt (adjusted prevalence ratio 1.42, 95% CI 1.14–1.77)[2]. Our guide to barriers to getting a GLP-1 prescription explains what the cohort measured.
In a separate program, 57 of 78 patients offered liraglutide declined, mainly because of out-of-pocket cost[3]. The liraglutide cost study reported greater weight loss among patients who opted in, but patients chose their treatment group.
Check whether your plan covers the prescription
In KFF’s 2026 survey, 18% of firms with at least 200 workers that offered health benefits reported covering GLP-1s for weight loss in their largest plan[4]. The employer coverage guide shows how to check the rules for your medication and intended use.
What people said they wanted
Among respondents, 89.5% wanted one place to track refills, prior authorization and appointments together, and 87.2% wanted to see prior-authorization status in real time. The survey asked about both features separately[1].
How to plan for delays
Ask your prescriber who submits the authorization and whom to contact about its status. If you’re considering self-pay, use the GLP-1 market guide to compare what the price includes and who coordinates follow-up and refills. Confirm the full cost and billing schedule before paying out of pocket.
Check the insurance coverage guide for the formulary and authorization questions to ask before filling a prescription. If you’re comparing self-pay quotes, the state price finder shows which published offers are available where you live.